var data={"title":"Dornase alfa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dornase alfa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6057?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dornase-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dornase alfa: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dornase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dornase alfa: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161836\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pulmozyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161837\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pulmozyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161871\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme;</li>\n      <li>\n        Mucolytic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161839\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis:</b> Inhalation: 2.5 mg daily through selected jet nebulizers in conjunction with a Pulmo-Aide, Pari-Proneb, Mobilaire, or Porta-Neb compressor system or eRapid Nebulizer System</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Patients unable to inhale or exhale orally throughout the entire treatment period may use Pari-Baby nebulizer. Some patients may benefit from twice daily administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parapneumonic pleural effusions and empyemas (off-label use):</b> Intrapleural: 5 mg (diluted in 30 mL of sterile water) administered twice daily &gt;2 hours after each intrapleural alteplase dose (with a 1-hour dwell time for each drug) for a total of 3 days (Rahman, 2011). Some clinicians suggest consideration of fibrinolytic use in patients in whom treatment with at least 24 hours of chest tube drainage has failed and who are poor surgical candidates (Hamblin, 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161855\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dornase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dornase alfa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Cystic fibrosis:</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants and Children &le;5 years: Not approved for use; however, studies using this therapy in small numbers of children as young as 3 months of age have reported efficacy and similar side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children &gt;5 years: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161840\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804875\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804876\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161821\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pulmozyme: 1 mg/mL (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161808\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161823\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: Prior to use, squeeze each ampul to check for leaks. Should not be diluted or mixed with any other drugs in the nebulizer, this may inactivate the drug. When administered with the eRapid Nebulizer System, replace handset after 90 uses to ensure delivery of appropriate dose; the eRapid Nebulizer System should only be used by patients who can use a mouthpiece.  Follow the manufacturer&rsquo;s instructions on use and maintenance of the equipment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parapneumonic pleural effusions and empyemas (off-label use): Intrapleural: <b>Note:</b> Each dose must be diluted in 30 mL of sterile water. Stability of dornase alfa diluted in sterile water has not been formally evaluated; use immediately after preparation. Instill dose  into chest tube and clamp drain. After 1 hour dwell time, release clamp and connect chest tube to continuous suction (Rahman, 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161822\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cystic fibrosis:</b> Management of cystic fibrosis patients, in conjunction with standard therapies, to improve pulmonary function; reduce the risk of respiratory tract infections requiring parenteral antibiotics in patients with a forced vital capacity (FVC) &ge;40% of predicted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474999\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Parapneumonic pleural effusions and empyemas (adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161815\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were similar in children using the PARI BABY nebulizer (facemask as opposed to mouthpiece) with the addition of cough.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (18% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Voice disorder (12% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (3% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (PARI-BABY nebulizer facemask: children 3 months to &lt;5 years: 45%; children 5 to &le;10 years: 30%), pharyngitis (32% to 40%), rhinitis (30%; in patients with FVC: &lt;40%), decrease in forced vital capacity (&ge;10% decrease of predicted: 22%; in patients with FVC: &lt;40%), dyspnea (17%; in patients with FVC: &lt;40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (32% in patients with FVC &lt;40%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Antibody development (to dornase alfa: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Laryngitis (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Headache, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161826\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dornase alfa, Chinese hamster ovary cell products, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161812\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Decreased pulmonary function: In patients with pulmonary function &lt;40% of normal, dornase alfa does not significantly reduce the risk of respiratory infections that require parenteral antibiotics. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Safety studies included children &ge;3 months, however experience is limited in children &lt;5 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299229\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219980\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9385&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5131960\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5131961\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Measurable amounts would not be expected in breast milk following inhalation; however, it is not known if dornase alfa is excreted in human milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161811\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The hallmark of cystic fibrosis lung disease is the presence of abundant, purulent airway secretions composed primarily of highly polymerized DNA. The principal source of this DNA is the nuclei of degenerating neutrophils, which is present in large concentrations in infected lung secretions. The presence of this DNA produces a viscous mucous that may contribute to the decreased mucociliary transport and persistent infections that are commonly seen in this population. Dornase alfa is a deoxyribonuclease (DNA) enzyme produced by recombinant gene technology. Dornase selectively cleaves DNA, thus reducing mucous viscosity and as a result, airflow in the lung is improved and the risk of bacterial infection may be decreased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161825\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Nebulization: Enzyme levels are measured in sputum in ~15 minutes and decline rapidly thereafter </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Sputum concentrations decline within 2 hours of inhalation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161828\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pulmozyme Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (2.5 mL): $137.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161829\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pulmozym (UA);</li>\n      <li>Pulmozyme (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HN, HR, HU, IE, IL, IS, IT, JM, JP, KW, LB, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PE, PL, PT, RO, RU, SE, SI, SK, SR, SV, TR, TT, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Albertson TE, Walby WF, Allen RP, et al. The Pharmacology and Toxicology of Three New Biologic Agents Used in Pulmonary Medicine. <i>J Toxicol Clin Toxicol</i>. 1995;33(5):427-438.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/7650767/pubmed\" target=\"_blank\" id=\"7650767\">7650767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. <i>Thorax</i>. 2010;65(suppl 2):ii41-ii53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/20696693/pubmed\" target=\"_blank\" id=\"20696693\">20696693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients With Cystic Fibrosis. <i>N Engl J Med</i>. 1994;331(10):637-642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/7503821/pubmed\" target=\"_blank\" id=\"7503821\">7503821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamblin SE, Furmanek DL. Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion. <i>Pharmacotherapy</i>. 2010;30(8):855-862.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/20653362/pubmed\" target=\"_blank\" id=\"20653362\">20653362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hubbard RC, McElvaney NG, Birrer P, et al. A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis. <i>N Engl J Med</i>. 1992;326(12):812-815.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/1538726/pubmed\" target=\"_blank\" id=\"1538726\">1538726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mueller GA, Rubins G, Wessel D, et al. Effects of Dornase Alfa on Pulmonary Function Tests in Infants with Cystic Fibrosis. <i>Am J Respir Crit Care Med</i>. 1996;153:A70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmozyme (dornase alfa) [prescribing information]. South San Francisco, CA: Genentech; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. <i>N Engl J Med</i>. 2011;365(6):518-526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/21830966/pubmed\" target=\"_blank\" id=\"21830966\">21830966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rock M, Kirchner K, McCubbin M, et al. Aerosol Delivery and Safety of rhDNASE in Young Children With Cystic Fibrosis: A Bronchoscopic Study. <i>Pediatr Pulmonol</i>. 1996;13(Suppl):A268.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suri R. The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis. <i>BioDrugs</i>. 2005;19(3):135-144.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/15984899/pubmed\" target=\"_blank\" id=\"15984899\">15984899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagener JS, Rock MJ, McCubbin MM, et al. Aerosol Delivery and Safety of Recombinant Human Deoxyribonuclease in Young Children With Cystic Fibrosis: A Bronchoscopic Study. Pulmozyme Pediatric Broncoscopy Study Group. <i>J Pediatr</i>. 1998; 133(4):486-491.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/9787685/pubmed\" target=\"_blank\" id=\"9787685\">9787685</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9385 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F161836\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F161837\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F161871\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F161839\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F161855\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F161840\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15804875\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15804876\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F161821\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F161808\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F161823\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F161822\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474999\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F161815\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F161826\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F161812\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299229\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219980\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5131960\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5131961\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F161811\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F161825\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F161828\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F161829\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9385|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dornase-alfa-patient-drug-information\" class=\"drug drug_patient\">Dornase alfa: Patient drug information</a></li><li><a href=\"topic.htm?path=dornase-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">Dornase alfa: Pediatric drug information</a></li></ul></div></div>","javascript":null}